Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Eugene Komchuk
Eugene Komchuk

REX launches Peptide ETF to target weight loss drug trend, Eric Balchunas notes

REX launches Peptide ETF to target weight loss drug trend, Eric Balchunas notes
REX launches Peptide ETF targeting drug trend

REX launched the Peptide ETF under ticker PEPT, which is aiming to capture the weight loss drug trend.

Eric Balchunas, who is a senior ETF analyst at Bloomberg Intelligence, reported the launch.

Balchunas has previously covered continued investor inflows into TLT despite persistent declines in value, as seen in his reporting on the bond ETF. He also reported on the personal impact of Yamo Pharma's phase 2 autism drug for the CEO of Defiance, with details from the ongoing trial. These articles highlight his focus on trending developments in both ETFs and biotech.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

The limits of progress: Why AI development could slow down
  • By Oleg Tkachenko
  • 6 hours ago
The limits of progress: Why AI development could slow down
Editors' Picks
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
  • By Dmytro Kharkov
  • 7 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
Editors' Picks
Tokens without buyers: Why NFT marketplaces are shutting down
  • By Mikhail Vnuchkov
  • Yesterday
Tokens without buyers: Why NFT marketplaces are shutting down
Editors' Picks
All Editors' Top Picks

Latest Eric Balchunas News

Eric Balchunas: Defiance CEO shares personal impact of Yamo Pharma phase 2 autism drug
  • By Ksenia Gerey
  • Yesterday
Eric Balchunas: Defiance CEO shares personal impact of Yamo Pharma phase 2 autism drug
Market Voices
#Eric Balchunas
Bloomberg plans 11th annual ETFs in Depth event featuring top industry panel, Eric Balchunas notes
  • By Yulia Slavina
  • 12.10.2026
Bloomberg plans 11th annual ETFs in Depth event featuring top industry panel, Eric Balchunas notes
Market Voices
#Eric Balchunas
Eric Balchunas: Corgi aims to become Wal-Mart of ETFs with expansion plans
  • By Elena Nikulina
  • 08.10.2026
Eric Balchunas: Corgi aims to become Wal-Mart of ETFs with expansion plans
Market Voices
#Eric Balchunas
All Eric Balchunas News
  • Oleg Tkachenko
  • 6 hours ago
The limits of progress: Why AI development could slow down
  • Dmytro Kharkov
  • 7 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
  • Mikhail Vnuchkov
  • Yesterday
Tokens without buyers: Why NFT marketplaces are shutting down
  • Alena Volkova
  • Yesterday
Is it bad to be rich: Why billionaires are seen as villains
  • Olena Litvinenko
  • 12.10.2026
What is a national blockchain network and does the world need one?
  • Yulia Slavina
  • 4 min ago
More AI applications will launch on WalrusProtocol, Adeniyi Abiodun notes
  • Daria Chernytska
  • 9 min ago
Suze Orman: Helping adult children gain financial independence is an act of love
  • Mykhailo Ihnatenko
  • 14 min ago
Daniel Kral: French government debt sell-off sparks wider eurozone spread rise
  • Hanna Syniavska
  • 19 min ago
Caleb Franzen: Behavior during BTC breakout and first consolidation defines success
  • Oksana Koneva
  • 24 min ago
A return to 2-3% Fed Funds could mean a harsh downturn, Michael Kao warns
Top News
  • Igor Krasulya
  • 19 min ago
Morgan Stanley tops Wall Street estimates as equity trading revenue soars
Morgan Stanley tops Wall Street estimates as equity trading revenue soars
  • Ivan Andriyenko
  • 1 hour ago
Oil prices advance amid new Iranian threats to tankers
Oil prices advance amid new Iranian threats to tankers
  • Ivan Andriyenko
  • 6 hours ago
Gold slips below $4,150 as Fed rate outlook weighs on bullion
Gold slips below $4,150 as Fed rate outlook weighs on bullion
  • Andrey Mastykin
  • 7 hours ago
Lagarde sees no wider inflation spillover as energy prices surge
Lagarde sees no wider inflation spillover as energy prices surge
  • Dmytro Kharkov
  • 7 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
Live News
  • Eugene Komchuk
  • Now
Crypto remittances from Canada to Asian countries reach nearly $2.4 billion
  • Aleksandra Chaikina
  • Now
Kraken owner Payward to acquire Lithuanian bank in EU expansion
  • Andrey Mastykin
  • Now
Wall Street futures diverge as inflation and earnings take focus
  • Anton Kharitonov
  • Now
EUR/USD faces renewed downside risks as markets await U.S. inflation report
  • Hanna Syniavska
  • Now
Goldman Sachs targets India and China as AI spending accelerates
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers